High quality Hyaluronic Acid
suitable for pharmaceutical and medical
Innovative technology for release
of active ingredients
for topical and transdermal use
from Altergon Italia R&D laboratories
the new frontier of Hyaluronic Acid
"In Altergon we work steadily to increase the safety and efficacy of our products, to improve the quality of our patients life”
Our strength is in combining the strict respect of the rules and ethical principles that govern the production of the drug, with the focus on innovation and scientific researchsee more
Un'innovativa C.D.M.O.-Contract Development & Manufacturing Organization- per proporre moderni sistemi di Drug Delivery alle società clienti.
We are pleased to inform you that the EDQM has released to Altergon Italia the renewed CEP (R1-CEP- 2014-263 rev. 00) on 22th January 2021.
Altergon Italia is pleased to inform you that a revised Certificate of Suitability (RO-CEP-2014-63 Rev 01) was issued by EDQM on March 31, 2020.
In March 2016, Altergon submitted to FDA (CDRH) the Master File for manufacturing Sodium Hyaluronate (MAF)
Altergon Italia is pleased to inform that our Ultrapure Hyaluronate successfully succeeded the Certificate of Suitability (CEP: R0-CEP 2014-263-Rev 00) to the European Pharmacopoeia, Sodium Hyaluronate Monograph granted by the EDQM.
From start-up to European leader in producing transdermal medicines
pag. 73 Platinum July 2015